In the ongoing fight to treat Alzheimer’s disease, the U.S. Food and Drug Administration (FDA) approved the drug Leqembi as a possible treatment on Jan. 6.
The approval is under the FDA’s Accelerated Approval pathway, which approves drugs for serious conditions where there is an unmet medical need.
While this may sound like promising news, you may be wondering: What is the new FDA-approved Alzheimer's drug and how does it slow cognitive decline?
